-
Product Insights
Cancer Anorexia-Cachexia Syndrome – Drugs In Development, 2023
Global Markets Direct’s, ‘Cancer Anorexia-Cachexia Syndrome - Drugs In Development, 2023’, provides an overview of the Cancer Anorexia-Cachexia Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cancer Anorexia-Cachexia Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Teicoplanin in Cystic Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Teicoplanin in Cystic Fibrosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Teicoplanin in Cystic Fibrosis Drug Details:Teicoplanin is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ACM-001 in Cancer Anorexia-Cachexia Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ACM-001 in Cancer Anorexia-Cachexia Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.ACM-001 in Cancer Anorexia-Cachexia SyndromeDrug Details:Espindolol (ACM-001) is under development for the...
-
Track & Monitor
Artificial Intelligence in Healthcare: Digital Pathology
Innovations in healthcare industry is relentless, making it hard to stay-on top of the dynamically evolving industry landscape and in early identification of profound shifts posing high risk of being disrupted if detected too late. GlobalData's coherent data-driven approach, using multiple forward-looking alternative datasets, empowers clients by decoding in advance the disruptive innovations in healthcare industry. Using patent data, GlobalData's proprietary industry innovation s-curve identifies specific innovation areas and their stage of evolution, i.e., whether they are emerging, accelerating or...
-
Company Insights
PT Bank Central Asia – Digital Transformation Strategies
Bank Central Asia has been focusing on emerging technologies as a part of its digital transformation strategies. The annual ICT spending of Bank Central Asia was estimated at $ 395.8 million in 2022. A major share of this spending is earmarked for acquiring software, ICT services, and hardware from vendors. Bank Central Asia (BCA) is a provider of personal, commercial, and corporate banking solutions. Its portfolio of products and services comprises savings accounts, time deposits, credit cards, debit cards, prepaid...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ACM-001
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry ACM-001 Drug Details Espindolol (ACM-001) is under development for the treatment of cachexia related...
-
Product Insights
Amyotrophic Lateral Sclerosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The symptoms of amyotrophic lateral sclerosis include difficulty breathing, difficulty swallowing, head drop due to weakness of the neck muscles, muscle cramps, speech problems, such as a slow or abnormal speech pattern (slurring of words), voice changes, hoarseness, weight loss. The Amyotrophic Lateral Sclerosis pipeline market research report provides comprehensive information on the therapeutics under development for Amyotrophic Lateral Sclerosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type....
-
Product Insights
Cancer Anorexia-Cachexia Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The Cancer Anorexia-Cachexia Syndrome pipeline market report provides a comprehensive overview of the therapeutics under development for Cancer Anorexia-Cachexia Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cancer Anorexia-Cachexia...
-
Product Insights
COVID 19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2021
COVID-19 enzyme immuno assay/enzyme linked immunosorbent assay (EIA/ELISA) is the most widely used assays having high sensitivity and specificity. They are used to detect the recombinant protein and peptide antigens in the samples. The COVID-19 EIA/ELISA pipeline product report provides comprehensive information about the pipeline products with comparative analysis at various stages of development and information about the clinical trials which are in progress. The report also provides key information and clinical trial data regarding ongoing clinical trials such as...
-
Product Insights
COVID 19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) – Medical Devices Pipeline Assessment, 2020
COVID 19 EIA/ELISA are the most widely used assays having high sensitivity and specificity. They are used to detect the recombinant protein and peptide antigens in the samples. ELISA’s are specifically designed to screen large number of samples at a time. GlobalData's Medical Devices sector report, “COVID 19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) -Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the COVID 19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) pipeline products with comparative analysis of...